10-K: CG Oncology Advances Bladder Cancer Therapy with Strong Phase 3 Data

CG Oncology, Inc. reports promising Phase 3 clinical trial data for its lead product candidate, cretostimogene, in high-risk NMIBC, initiating BLA submission and expanding its bladder cancer pipeline.

Summary

• CG Oncology is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an oncolytic immunotherapy for bladder cancer.
• The company initiated its Biologics License Application (BLA) submission to the FDA in Q4 2025 for high-risk Bacillus Calmette-Gurin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without Ta/T1 disease, based on positive Phase 3 BOND-003 Cohort C data.
• Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for high-risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 papillary tumors.
• Phase 3 BOND-003 Cohort C showed a 75.5% complete response (CR) at any time, with 41.8% of evaluable responders maintaining CR at 24 months, and 96.6% of patients free from progression to muscle invasive disease at 24 months.
• The company completed enrollment for its Phase 3 PIVOT-006 trial in intermediate-risk NMIBC in Q3 2025, with topline data expected in H1 2026.
• Initial data from Phase 2 CORE-008 Cohort A in high-risk BCG-nave NMIBC showed an 83.7% overall CR rate at any time.
• Net loss for the year ended December 31, 2025, was $161.0 million, compared to $88.0 million in 2024.
• Research and development expenses increased to $116.6 million in 2025 from $82.1 million in 2024, driven by higher clinical trial costs and personnel expenses.
• General and administrative expenses rose to $73.5 million in 2025 from $33.7 million in 2024, primarily due to increased compensation, professional fees, and marketing costs.
• As of December 31, 2025, the company held $742.2 million in cash, cash equivalents, and marketable securities.
• The company acquired a controlling interest in Biovire, a contract manufacturing organization, in July 2025, to strengthen its manufacturing supply continuity.
• A legal proceeding with ANI Pharmaceuticals, Inc. regarding royalty payments was resolved in the company's favor by a jury verdict in July 2025, rejecting ANI's claims for unjust enrichment damages.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, driven by robust Phase 3 clinical data for cretostimogene, the initiation of a BLA submission, and a strong financial position, which collectively de-risk the company's lead asset and future commercial prospects, despite ongoing operating losses.

Positives

• Cretostimogene demonstrated strong efficacy in Phase 3 BOND-003 Cohort C with a 75.5% complete response (CR) at any time and 41.8% CR maintained at 24 months, indicating best-in-disease durability.
• The safety and tolerability profile of cretostimogene is favorable, with no Grade 3 or higher treatment-related adverse events (TRAEs) and no treatment discontinuations due to TRAEs in BOND-003 Cohort C.
• Cretostimogene's administration method is simple and similar to standard-of-care BCG therapy, potentially driving increased physician adoption.
• The product candidate has received Fast Track and Breakthrough Therapy designations from the FDA, which may expedite development and regulatory review.
• Enrollment for the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC was completed approximately one year ahead of schedule, highlighting strong interest and unmet need.
• Initial data from Phase 2 CORE-008 Cohort A in high-risk BCG-nave NMIBC showed promising clinical efficacy with an 83.7% overall CR rate at any time.
• The acquisition of Biovire, a contract manufacturing organization, in July 2025, strengthens the company's manufacturing supply chain for cretostimogene.
• The company successfully defended against a lawsuit from ANI Pharmaceuticals, Inc., with a jury rejecting all claims for unjust enrichment damages, avoiding a potential 5% royalty on net sales of cretostimogene.
• The company has a strong cash position with $742.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Negatives

• The company incurred significant operating losses of $161.0 million in 2025 and $88.0 million in 2024, with an accumulated deficit of $379.0 million as of December 31, 2025.
• The business currently depends entirely on the success of cretostimogene, its only product candidate, making it riskier than companies with diversified pipelines.
• The company has a relatively limited operating history and no products approved for commercial sale, with no revenue generated from product sales to date.
• Substantial additional capital will be required to finance operations, complete development, obtain regulatory approvals, and commercialize cretostimogene.
• The novel approach of cretostimogene (replication-competent adenovirus) may create challenges in obtaining regulatory approval and could lengthen the review process.
• The company relies heavily on third parties for clinical trials, manufacturing, and shipping, which introduces risks of delays, non-compliance, or insufficient supply.
• The ongoing global shortage of BCG therapy, while creating an unmet need, also means that if Merck or other manufacturers increase BCG supply, demand for alternative treatments like cretostimogene could decrease.
• The company is in the early stages of building its internal marketing and sales organization and has no prior experience commercializing products, requiring significant resource investment.

Risks

• Dependence entirely on the success of cretostimogene; failure or delays in development, approval, or commercialization would materially harm the business.
• Cretostimogene's novel approach makes predicting development time, cost, and regulatory approval difficult, potentially lengthening the review process and increasing costs.
• Clinical and preclinical drug development is lengthy, expensive, and uncertain; results from early trials are not necessarily predictive of future results, and product candidates can fail at any stage.
• Use of cretostimogene could be associated with adverse side effects or safety risks, potentially delaying or precluding regulatory approval, causing trial suspension, or limiting commercial profile.
• Interim, topline, and preliminary data may change as more patient data become available and are subject to audit and verification, potentially resulting in material changes in final data.
• A Breakthrough Therapy designation may not lead to faster development or approval and does not increase the likelihood of FDA approval.
• Reliance on third parties to conduct clinical trials and preclinical studies; failure of these parties to perform contractual duties, comply with regulations, or meet deadlines could delay development and approval.
• Reliance on Biovire and other third parties for manufacturing, supply, and shipping increases the risk of insufficient quantities or unacceptable costs, impairing development or commercialization.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and potential restrictions on use or marketing.
• Significant competition from established pharmaceutical and biotechnology companies, as well as academic institutions, could lead to competitors developing more effective, safer, or less expensive treatments.
• Limited operating history, significant operating losses, and expectation of continued losses for the foreseeable future; profitability is not guaranteed and may not be sustainable.
• Requirement for substantial additional capital to finance operations; failure to obtain necessary capital could force delays, reductions, or termination of development and commercialization efforts.
• Inability to obtain, maintain, and enforce patent or other intellectual property protection for cretostimogene or future product candidates, or if the scope of protection is insufficient, competitors could commercialize similar products.
• Changes in patent laws or their interpretation could diminish the value of patents, impairing the ability to protect products.
• Potential for product liability lawsuits, which could result in substantial liabilities, require limiting or ceasing commercialization, and incur significant defense costs.
• Exposure to various U.S. federal, state, and foreign healthcare laws and regulations (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), increasing compliance costs and potential for significant fines or liability.
• Unstable market and economic conditions, including inflation, and adverse developments with financial institutions, may seriously affect business, financial condition, and stock price.
• Cybersecurity threats to information technology systems and data could lead to material disruption, compromise sensitive information, or expose the company to liability.

Future Outlook

The company expects to complete its Biologics License Application (BLA) submission for cretostimogene in high-risk BCG-unresponsive NMIBC in 2026. It plans to expand the development of cretostimogene as a potential backbone therapy across various NMIBC indications, including intermediate-risk, BCG-exposed, and BCG-nave patients, with topline data from the PIVOT-006 trial expected in the first half of 2026. The company also intends to continue evaluating cretostimogene in combination with other therapies and is building its internal commercial organization in preparation for potential FDA approval and product launch.

Management Comments

• We believe cretostimogene, if approved in intermediate-risk NMIBC, has the potential to serve as a first-in-class backbone therapy in this frontline adjuvant setting, for which there are currently no U.S. FDA approved options.
• Our goal is to develop cretostimogene as a bladder-sparing backbone therapeutic for patients afflicted with bladder cancer.
• We believe cretostimogene, if approved, has the potential to address the significant unmet need in bladder cancer treatment.
• We believe our approach to combine cretostimogene with other therapeutics across several bladder cancer indications may enhance the potential utility of our product candidate beyond our core strategy of targeting intermediateand high-risk NMIBC via cretostimogene monotherapy.
• We believe this concentration [of urology practices] will potentially enable us to efficiently reach a large portion of our addressable market with a relatively small commercial footprint.
• We believe our strategic CMC approach will potentially enable us to maintain an attractive cost of goods while rapidly achieving commercial scalability, if cretostimogene receives FDA approval.

Industry Context

StockSavvy.ai notes that the bladder cancer market, particularly NMIBC, presents a significant unmet medical need due to high recurrence rates, patient aversion to radical cystectomy, and chronic shortages of the standard-of-care BCG therapy. CG Oncology's focus on a bladder-sparing oncolytic immunotherapy positions it to address these critical gaps. The immuno-oncology field is highly competitive, with several companies developing novel treatments, but cretostimogene's dual mechanism of action and strong durability data could differentiate it. The ongoing BCG shortage further emphasizes the market opportunity for effective alternatives.

Comparison to Industry Standards

• **Cretostimogene (CG Oncology):** 75.5% CR (any time), 41.8% CR at 24 months, 96.6% free from progression to MIBC at 24 months, no Grade 3 or higher TRAEs, median DOR 28 months (ongoing).
• **Pembrolizumab (Merck):** 41% CR at 3 months, 19% CR at 12 months in CIS cohort; 13% Grade 3 or 4 toxicities, 7% discontinuations due to TRAEs. (Comparison: Cretostimogene shows superior durability and a significantly better safety profile.)
• **Nadofaragene firadenovec (Ferring):** 51% CR, 24% CR at 12 months; 4% Grade 3 or 4 TRAEs, 2% serious TRAEs. (Comparison: Cretostimogene demonstrates higher CR rates and better durability at 24 months, with a more favorable safety profile.)
• **Gemcitabine intravesical system (TAR-200, Johnson & Johnson):** 82% CR, 51% CR with DOR ≥ 12 months; 13% Grade 3 TRAEs, 6% serious AEs, 3.5% discontinuations. (Comparison: Cretostimogene's 24-month durability is competitive, and its safety profile appears superior with no Grade 3+ TRAEs.)
• **ZUSDURI (mitomycin, Urogen Pharma):** 78% CR at 3 months, 79% maintained CR at 12 months (for LG-IR-NMIBC); mild to moderate TRAEs >10%, 12% serious adverse reactions. (Comparison: ZUSDURI is for low-grade NMIBC, while cretostimogene targets high-risk, BCG-unresponsive NMIBC, making direct comparison difficult, but cretostimogene's safety profile remains strong.)
• **Nogapendekin alfa inbakicept (ImmunityBio) + BCG:** 62% CR, 36% CR at 12 months; 16% serious TRAEs, 7% discontinuations. (Comparison: Cretostimogene monotherapy shows higher CR rates and better durability than nogapendekin in combination with BCG, with a superior safety profile.)

Corporate Governance

Legal Proceedings

• On March 4, 2024, ANI Pharmaceuticals, Inc. filed a complaint against the company in the Superior Court of the State of Delaware seeking a declaratory judgment for a 5% royalty on net sales of cretostimogene and compensatory damages for unjust enrichment.
• On July 16, 2025, the Superior Court granted the company's motion for summary judgment regarding ANI's royalty claims but denied the motion for the unjust enrichment claim.
• On July 29, 2025, a jury entered a verdict in favor of the company, unanimously rejecting all of ANI's claims for unjust enrichment damages, meaning no future royalty or damages are owed to ANI under the ANI Agreement.
• ANI Pharmaceuticals, Inc. is expected to pursue post-trial motions and appeals, which the company intends to vigorously defend.

Stakeholder Impact

• **Shareholders:** Potential for increased stock value due to strong clinical data, BLA submission, and progress towards commercialization, but also risk of dilution from future capital raises and continued operating losses.
• **Patients (Bladder Cancer):** Significant positive impact through the potential availability of a new, effective, bladder-sparing treatment option (cretostimogene) with a favorable safety profile, addressing a high unmet medical need, especially for BCG-unresponsive and intermediate-risk NMIBC.
• **Employees:** Growth opportunities and potential for increased headcount in R&D and commercialization, with stock-based compensation as a key incentive.
• **Third-Party Manufacturers/Suppliers:** Continued reliance on these partners for manufacturing and supply, with the acquisition of Biovire strengthening control over a portion of the supply chain.
• **Regulatory Bodies (FDA):** Active engagement through BLA submission, Fast Track, and Breakthrough Therapy designations, requiring ongoing compliance and review.
• **Healthcare Providers (Urologists):** Potential for a new, easy-to-administer treatment option that aligns with existing practice workflows, addressing limitations of current therapies like BCG shortages and radical cystectomy.

Next Steps

• Complete the Biologics License Application (BLA) submission for cretostimogene to the FDA in 2026.
• Report topline data from the Phase 3 PIVOT-006 clinical trial in intermediate-risk NMIBC in the first half of 2026.
• Report first results from the Phase 2 CORE-008 Cohort CX trial (cretostimogene in combination with gemcitabine) in the first half of 2026.
• Continue to expand the development of cretostimogene monotherapy across NMIBC indications (BCG-exposed and BCG-nave).
• Build out internal marketing and sales organization and commercial infrastructure in preparation for potential FDA regulatory approval and commercial launch of cretostimogene.
• Establish long-term supply agreements with third-party manufacturers and evaluate additional product manufacturing sources to de-risk the supply chain.
• Vigorously defend against any post-trial motions and appeals brought by ANI Pharmaceuticals, Inc.

Key Dates

Recommendation

The filing presents compelling evidence of cretostimogene's efficacy and safety in high-risk NMIBC, with 'best-in-disease' durability data and no Grade 3+ TRAEs. The initiation of the BLA submission is a critical de-risking event, signaling imminent market entry for a product addressing a significant unmet need. The expedited enrollment in PIVOT-006 and positive early data in BCG-nave patients further expand the market opportunity. While the company is pre-revenue and incurring losses, its substantial cash reserves and successful legal defense against a potential royalty obligation provide a strong financial runway. The combination of strong clinical data, clear regulatory path, and market potential makes this a 'strong buy' for long-term investors.

Keywords

Bladder Cancer, NMIBC, Oncolytic Immunotherapy, Cretostimogene, BCG-unresponsive, Clinical Trials, Phase 3, FDA Approval, Biologics License Application, Biopharmaceutical, Oncology, Drug Development, Biovire, Capital Raise, Intellectual Property